Bcl-2 pathway inhibition in solid tumors: a review of clinical trials
-
Ioanna Ploumaki [1] ; Efthymios Triantafyllou [1] ; Ioannis-Alexios Koumprentziotis [1] ; Konstantinos Karampinos [1] ; Konstantinos Drougkas [1] ; Ioannis Karavolias [1] ; Ioannis Trontzas [1] ; EliasA. Kotteas [1]
-
[1] National and Kapodistrian University of Athens
National and Kapodistrian University of Athens
Dimos Athens, Grecia
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 6, 2023, págs. 1554-1578
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Due to their key role in the pathogenesis of cancer through the regulation of apoptosis, the B-cell leukemia/lymphoma-2 (BCL-2) family proteins have been an attractive target for cancer therapy for the past decades. Throughout the years, many Bcl-2 family inhibitors have been developed, with Venetoclax being now successfully used in treating hematological malignancies. Although their effectiveness in the treatment of solid tumors is yet to be established, some preclinical evidence indicates their possible clinical application. This review aims to summarize current data from completed clinical trials that used Bcl-2 protein family inhibitors as monotherapy or in combination with other agents for the treatment of solid malignancies. We managed to include clinical trials of various phases which analyze the pharmacokinetics and pharmacodynamics of the drugs, as well as the effectiveness and adverse effects. Active and recruiting clinical trials are also briefly presented and future prospects and challenges are discussed.
